Aclaris Therapeutics, Inc. (ACRS)
NASDAQ · Manufacturing · Pharmaceutical preparations
ACRS price, last 12 months
Key stats
- Previous close
- $3.50
- Open
- $3.53
- Day range
- $3.44 – $3.62
- 52-week range
- $2.34 – $6.60
- Volume
- 1.9M
- Avg volume (20 days)
- 2.8M
- Market cap
- $621.8M
Performance
Technicals and fundamentals
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $621.8M